This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Retailers accuse Takeda, TWi Pharmaceuticals of blocking generic competition for Dexilant

( March 25, 2025, 17:53 GMT | Official Statement) -- MLex Summary: Walgreen Co., The Kroger Co., Albertsons, and HEB filed a complaint accusing Takeda Pharmaceutical and Twi Pharmaceuticals of entering into an illegal reverse payment agreement to restrain competition in the US market for Dexilant and its generic equivalents. According to the complaint, the scheme was consistent with a broader effort by Takeda to unlawfully thwart generic competition against its branded products, which provide treatment for erosive esophagitis and symptoms of gastroesophageal reflux disease.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections